drugset
drugset / Trial / NCT03951337

64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)

NCT03951337 ↗

Phase 2 Unknown 70 enrolled Institut Cancerologie de l'Ouest Fondation ARC · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This phase II trial is assessing how 64Cu-ATSM (64Cu-copper(II) diacetylbis(N4-methylthiosemicarbazone)) PET/CT scan could predict neo adjuvant treatment response in rectum cancer locally advanced

Timeline

Start
2019-04-26
Primary completion
2024-07
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 64Cu-ATSM Unknown 3 mbq/kg Intravenous

Indications

rectal cancer